Does PALIVIZUMAB Cause Salivary hypersecretion? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Salivary hypersecretion have been filed in association with PALIVIZUMAB (Synagis). This represents 0.1% of all adverse event reports for PALIVIZUMAB.
8
Reports of Salivary hypersecretion with PALIVIZUMAB
0.1%
of all PALIVIZUMAB reports
0
Deaths
7
Hospitalizations
How Dangerous Is Salivary hypersecretion From PALIVIZUMAB?
Of the 8 reports, 7 (87.5%) required hospitalization.
Is Salivary hypersecretion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALIVIZUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does PALIVIZUMAB Cause?
Respiratory syncytial virus infection (1,692)
Pyrexia (1,055)
Death (856)
Bronchiolitis (724)
Cough (665)
Pneumonia (657)
Dyspnoea (466)
Nasopharyngitis (462)
Vomiting (445)
Influenza (398)
What Other Drugs Cause Salivary hypersecretion?
CLOZAPINE (1,349)
ARIPIPRAZOLE (497)
RISPERIDONE (485)
OLANZAPINE (449)
QUETIAPINE (299)
CARBIDOPA\LEVODOPA (248)
HALOPERIDOL (216)
DIAZEPAM (185)
CLONAZEPAM (179)
LORAZEPAM (165)
Which PALIVIZUMAB Alternatives Have Lower Salivary hypersecretion Risk?
PALIVIZUMAB vs PALONOSETRON
PALIVIZUMAB vs PAMIDRONATE
PALIVIZUMAB vs PAMIDRONIC ACID
PALIVIZUMAB vs PANCRELIPASE
PALIVIZUMAB vs PANCRELIPASE AMYLASE\PANCRELIPASE LIPASE\PANCRELIPASE PROTEASE